NCT02631499View on ClinicalTrials.gov

Efficacy Study of TACE to Treat Hepatocellular Carcinoma After Operation

PHASE4UnknownINTERVENTIONAL
Enrollment

256

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

December 31, 2018

Study Completion Date

December 31, 2019

Conditions
Carcinoma, HepatocellularNeoplastic Cells, Circulating
Interventions
PROCEDURE

TACE

TACE is performed 4-6 weeks after hepatectomy. Epirubicin and lipiodol are used in TACE.

DRUG

Epirubicin

Epirubicin is a chemotherapy drug used in TACE

DRUG

lipiodol

lipiodol is a kind of embolization material used in TACE

Trial Locations (6)

200000

Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai

Xinhua Hospital, Affliated with Shanghai Jiao Tong University, School of Medicine, Shanghai

Zhongshan hospital, Fudan University, Shanghai

215000

The First Affiliated Hospital of Soochow University, Suzhou

226000

Nantong Tumor Hospital, Nantong

510000

Sun Yat-Sen University Cancer Center, Guangzhou

Sponsors
All Listed Sponsors
collaborator

Shanghai Zhongshan Hospital

OTHER

collaborator

Johnson & Johnson Medical, China

INDUSTRY

lead

Fudan University

OTHER